Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F573 for injection in liver injury/failure
NCT05689645Phase 2Recruiting
- Sponsor
- Gyre Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of F573 in drug induced liver injury (DILI), Chronic Hepatitis B (CHB), Intrahepatic Cholestatic Liver Injury, acute-on-chronic liver failure (ACLF), sponsored by Gyre Pharmaceuticals. Started Mar 2023; status: recruiting.
02
Drugs
F573
03
Conditions
drug induced liver injury (DILI)Chronic Hepatitis B (CHB)Intrahepatic Cholestatic Liver Injuryacute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT05689645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689645.